1446330-55-7

Basic information

• Product Name: 3-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-2H-chromen-2-one
• Synonyms: 3-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-2H-chromen-2-one
• CAS NO: 1446330-55-7
• Molecular Weight: 366.417
• Mol File: 1446330-55-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-2H-chromen-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-2H-chromen-2-one(1446330-55-7)
• EPA Substance Registry System: 3-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-2H-chromen-2-one(1446330-55-7)

Safety Data

• Hazardous Substances Data: 1446330-55-7(Hazardous Substances Data)

Upstream product

• 1446332-69-9 tert-butyl 4-(4-formyl-3-hydroxyphenyl)piperazine-1-carboxylate 
• 348-28-7 4-fluoro-2-hydroxybenzaldehyde 
• 110-85-0 piperazine 
• 1446333-58-9 3-(3,4-dimethoxyphenyl)-7-fluoro-2H-chromen-2-one 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 

Relevant articles and documents

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

The underlying cause of spinal muscular atrophy (SMA) is a deficiency of the survival motor neuron (SMN) protein. Starting from hits identified in a high-throughput screening campaign and through structure-activity relationship investigations, we have developed small molecules that potently shift the alternative splicing of the SMN2 exon 7, resulting in increased production of the full-length SMN mRNA and protein. Three novel chemical series, represented by compounds 9, 14, and 20, have been optimized to increase the level of SMN protein by >50% in SMA patient-derived fibroblasts at concentrations of 160 nM. Daily administration of these compounds to severe SMA Δ7 mice results in an increased production of SMN protein in disease-relevant tissues and a significant increase in median survival time in a dose-dependent manner. Our work supports the development of an orally administered small molecule for the treatment of patients with SMA.

COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.